BDBM255474 US9481688, 1::US9481688, 3
SMILES Cc1ccc2N=C(N3CCN(CC(C)(C)C(O)=O)CC3)c3cc(Cl)sc3Oc2c1
InChI Key InChIKey=PSYAJOBNPBYKRW-UHFFFAOYSA-N
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 24 hits for monomerid = 255474
Affinity DataKi: 3.37nM ΔG°: -11.6kcal/molepH: 7.6 T: 2°CAssay Description:[3H]-Ketanserin binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressi...More data for this Ligand-Target Pair
Affinity DataKi: 7.01nM ΔG°: -11.1kcal/molepH: 7.6 T: 2°CAssay Description:[3H]-Ketanserin binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressi...More data for this Ligand-Target Pair
Affinity DataKi: 20.6nM ΔG°: -10.5kcal/molepH: 7.6 T: 2°CAssay Description:[3H]-Pyrilamine binding experiments are carried out in SPA (scintillation proximity assay) 96-well format. Membranes used in this assay are prepared ...More data for this Ligand-Target Pair
Affinity DataKi: 58.8nM ΔG°: -9.86kcal/molepH: 7.6 T: 2°CAssay Description:[3H]-Pyrilamine binding experiments are carried out in SPA (scintillation proximity assay) 96-well format. Membranes used in this assay are prepared ...More data for this Ligand-Target Pair
Affinity DataKi: 121nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: 137nM ΔG°: -9.36kcal/moleT: 2°CAssay Description:[125I]-(±)DOI binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressing...More data for this Ligand-Target Pair
Affinity DataKi: 328nM ΔG°: -8.84kcal/moleT: 2°CAssay Description:[125I]-(±)DOI binding experiments are carried out in SPA 96-well format. Membranes used in this assay are prepared from AV-12 cells stably expressing...More data for this Ligand-Target Pair
Affinity DataKi: 592nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >2.06E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: 2.78E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >3.98E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >4.23E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >4.57E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >5.51E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >5.58E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >5.68E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >5.76E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >5.83E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >8.81E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >8.99E+3nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >1.02E+4nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataKi: >1.47E+4nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataEC50: >1.00E+4nMAssay Description:Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologicall...More data for this Ligand-Target Pair
Affinity DataIC50: >1.00E+5nMAssay Description:Activity of compounds on native GABAA receptors is evaluated by monitoring calcium fluxes using a 96 well format FLIPR system (Fluorometric Imaging P...More data for this Ligand-Target Pair